A detailed history of Verition Fund Management LLC transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 166,957 shares of ATNM stock, worth $215,374. This represents 0.0% of its overall portfolio holdings.

Number of Shares
166,957
Previous 140,519 18.81%
Holding current value
$215,374
Previous $1.04 Million 69.87%
% of portfolio
0.0%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.72 - $8.0 $45,473 - $211,504
26,438 Added 18.81%
166,957 $313,000
Q2 2024

Aug 14, 2024

SELL
$6.56 - $9.89 $366,822 - $553,029
-55,918 Reduced 28.47%
140,519 $1.04 Million
Q1 2024

May 14, 2024

BUY
$5.0 - $9.2 $982,185 - $1.81 Million
196,437 New
196,437 $1.54 Million
Q1 2023

May 15, 2023

BUY
$8.51 - $14.26 $149,061 - $249,778
17,516 New
17,516 $165,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $32.5M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.